PLUS THERAPEUTICS, Inc. (PSTV)
PSTV moved a median of -0.95% 30 minutes after news, and -2.27% by the close. How PSTV actually reacts to news — the realized, point-in-time move the market made, measured across 336 labeled events over the last three years with zero look-ahead.
PSTV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.11% | 32% | 314 |
| 30-min | -0.95% | 35% | 334 |
| 60-min | -1.06% | 36% | 335 |
| to close | -2.27% | 36% | 336 |
| Middle 50% of PSTV reactions | -3.35% to +1.45% |
|---|---|
| Median reaction (30-min) | -0.95% |
| Measured reactions | 336 |
Half of all PLUS THERAPEUTICS, Inc. news events land between -3.35% and +1.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PSTV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 48 | -1.72% | 27% | -2.33% |
| Price-target cuts | 10 | +0.38% | 50% | -1.85% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how PSTV ranks against every other measured name →
That’s how PSTV usually reacts — get an email when it moves on news →Email me when PSTV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PSTV's baseline. Nothing else.
Recent PSTV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cerenome Launches as an Integrated CNS Oncology Company | Press release | GlobeNewswire | +2.47% | +6.03% | |
| Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference | Press release | GlobeNewswire | -0.40% | -0.53% | |
| Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer | Press release | GlobeNewswire | +1.53% | +0.26% | |
| Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform | Press release | GlobeNewswire | -0.49% | -3.70% | |
| Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring | Press release | GlobeNewswire | -2.59% | +0.71% | |
| Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding | Press release | GlobeNewswire | -0.46% | +1.39% | |
| Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer | Press release | GlobeNewswire | -0.25% | +6.23% | |
| Plus Therapeutics to Provide Business Update Call on June 30, 2026 | Press release | GlobeNewswire | +2.30% | +4.35% | |
| Form S-8 PLUS THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | -2.18% | -3.63% | |
| Form EFFECT PLUS THERAPEUTICS, INC. | SEC filing · Form EFFECT | SEC EDGAR | +0.76% | +4.54% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +4.54% | |
| Form S-3/A PLUS THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | -0.45% | -3.39% | |
| Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory | Press release | GlobeNewswire | -0.56% | +6.19% | |
| Form S-3 PLUS THERAPEUTICS, INC. | SEC filing · Form S-3 | SEC EDGAR | -3.20% | -2.67% | |
| Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases | Press release | GlobeNewswire | +0.00% | -2.94% | |
| Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology | Press release | GlobeNewswire | -6.20% | -2.35% | |
| Form 10-Q PLUS THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.45% | +11.88% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +3.45% | +11.88% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +3.45% | +11.88% | |
| Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout | Press release | GlobeNewswire | +3.45% | +11.88% | |
| Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases | Press release | GlobeNewswire | -1.46% | +1.32% | |
| Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic | Press release | GlobeNewswire | +0.80% | -5.25% | |
| Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer | Press release | GlobeNewswire | +2.38% | +1.36% | |
| Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ | Press release | GlobeNewswire | -0.27% | -3.70% | |
| Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.27% | -3.70% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | -4.80% | |
| Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | -1.93% | -4.80% | |
| Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution | Press release | GlobeNewswire | +3.79% | +1.99% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +5.75% | +25.24% | |
| Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline | Press release | GlobeNewswire | +5.75% | +25.24% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +0.00% | |
| Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas | Press release | GlobeNewswire | +2.05% | +0.00% | |
| Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption | Press release | GlobeNewswire | -1.05% | -8.13% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -4.86% | |
| Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives | Press release | GlobeNewswire | -2.35% | -5.07% | |
| Form ARS PLUS THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.28% | +2.50% | |
| Form DEF 14A PLUS THERAPEUTICS, INC. For: May 14 | SEC filing · Form DEF | SEC EDGAR | -1.28% | +2.50% | |
| Form DEFA14A PLUS THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -1.28% | +2.50% | |
| Plus Therapeutics Announces Reverse Stock Split | Press release | GlobeNewswire | +2.35% | -2.11% | |
| Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.28% | +2.50% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | +0.54% | |
| Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors | Press release | GlobeNewswire | +0.95% | +0.54% | |
| Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% | Press release | GlobeNewswire | -1.25% | +0.08% | |
| Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.46% | -9.09% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -5.46% | -9.09% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -5.46% | -9.09% | |
| Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout | Press release | GlobeNewswire | -5.46% | -9.09% | |
| Form RW PLUS THERAPEUTICS, INC. | SEC filing · Form RW | SEC EDGAR | +2.30% | +4.31% | |
| Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ | Press release | GlobeNewswire | +2.47% | +9.53% | |
| Form 8-K PLUS THERAPEUTICS, INC. For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +0.14% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PSTV section they belong to.
Where else PSTV is measured.
PSTV earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PLUS THERAPEUTICS, Inc.'s median reaction calculated?
Every labeled PSTV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 336 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of PSTV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PSTV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.